- With a population close to 130 million people, Mexico is among the top 15 economies worldwide
and second largest in Latin
America. Approximately 11.7 million people have conditions
treatable with medical cannabis (Source: IMS Quintiles)
- Leveraging its Project of National Strategic Interest (PINES)
designation, Khiron receives THC extract export quota for
Mexico from Colombia, for up to 700 Kg of extract and
finished medical product
- Khiron has finalized agreements for the manufacture and
distribution of finished medical cannabis products in Mexico, establishing a key component of its
Mexican supply chain
- Company plans to launch Zerenia™ clinics across major cities in
Mexico in 2021, building on the
success of its vertically integrated model in Colombia and Peru and leveraging its education partnership
with Tecnologico de Monterrey
- With over 24,000 prescriptions sold in Colombia and Peru, Khiron is the leading medical cannabis
companies in Latin America
TORONTO, June 28, 2021 /CNW/ - Khiron Life Sciences Corp.
("Khiron" or the "Company") (TSXV: KHRN)(OTCQX: KHRNF)(Frankfurt: A2JMZC), a vertically integrated
medical cannabis leader with core operations in Latin America and Europe, today announces regulatory and supply
chain advances that accelerate Khiron's entry into the Mexican
market by several months. Leveraging the Company's designation in
Colombia as a National Strategic
Project, Khiron Colombia SAS has received authorization to include
Mexico as a destination country
within its international export quota, with over 700 kg of high-THC
extract now available for export to Mexico. In addition, the Company has finalized
agreements for the manufacture of finished medical cannabis
products in Mexico.
"Our goal is to improve the lives of 1 million patients by 2024,
and Mexico remains a very
important part of that plan. Thanks to our status as a National
Strategic Project, Mexico is now a
destination country within our international THC quota, which is
expected to accelerate first sales by several months. In addition,
we have secured a world class partner that will not only
manufacture finished products on our behalf, but also assist with
the import and export process. As we continue to advance our proven
Zerenia™ clinic strategy in Mexico, we look forward to delivering our
first products to patients in the coming months," comments
Alvaro Torres, CEO and Director.
Mexico represents a significant
market for the Company, as a top 15 global economy with a
population of nearly 130 million. To date, close to 550 LatAm
physicians have obtained their diploma accrediting completion of
Khiron's medical education program, in partnership with Tecnologico
de Monterrey, the leading
university in Mexico.
About Khiron Life Sciences Corp.
Khiron is a leading vertically integrated medical cannabis
company with core operations in Latin
America and Europe.
Leveraging wholly-owned medical health centres and proprietary
telemedicine platforms, Khiron combines a patient-oriented
approach, physician education programs, scientific expertise,
product innovation, and agricultural infrastructure to drive
prescriptions and brand loyalty with patients worldwide. The
Company has a sales presence in Colombia, Peru, Germany
and the UK, and is positioned to commence sales in Mexico and Brazil in 2021. The Company is led by
Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and
diverse executive team and Board of Directors.
Visit Khiron online at investors.khiron.ca and on Instagram
@khironlife.
Cautionary Notes
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment on
analyses, expectations or statements made by third-parties in
respect of Khiron, its securities, or financial or operating
results (as applicable). Although Khiron believes that the
expectations reflected in forward-looking statements in this press
release are reasonable, such forward-looking statement has been
based on expectations, factors and assumptions concerning future
events which may prove to be inaccurate and are subject to numerous
risks and uncertainties, certain of which are beyond Khiron's
control, including the risk factors discussed in Khiron's Annual
Information Form which is available on Khiron's SEDAR profile at
www.sedar.com. The forward-looking information contained in this
press release is expressly qualified by this cautionary statement
and is made as of the date hereof. Khiron disclaims any intention
and has no obligation or responsibility, except as required by law,
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this press release.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/khiron-accelerates-entry-into-mexico-awarded-high-thc-extract-export-quotas-for-mexico-by-the-government-of-colombia-301320951.html
SOURCE Khiron Life Sciences Corp.